These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 16506440)

  • 1. Molecular rationale for the pharmacological treatment of Alzheimer's disease.
    Zimmermann M; Gardoni F; Di Luca M
    Drugs Aging; 2005; 22 Suppl 1():27-37. PubMed ID: 16506440
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disease-modifying therapies in Alzheimer's disease: how far have we come?
    Hüll M; Berger M; Heneka M
    Drugs; 2006; 66(16):2075-93. PubMed ID: 17112302
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proteolytic processing of the Alzheimer's disease amyloid precursor protein in brain and platelets.
    Evin G; Zhu A; Holsinger RM; Masters CL; Li QX
    J Neurosci Res; 2003 Nov; 74(3):386-92. PubMed ID: 14598315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BACE1: the beta-secretase enzyme in Alzheimer's disease.
    Vassar R
    J Mol Neurosci; 2004; 23(1-2):105-14. PubMed ID: 15126696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Secretase inhibitors for Alzheimer's disease: challenges of a promiscuous protease.
    Pollack SJ; Lewis H
    Curr Opin Investig Drugs; 2005 Jan; 6(1):35-47. PubMed ID: 15675602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. APP, Notch, and presenilin: molecular pieces in the puzzle of Alzheimer's disease.
    Wolfe MS
    Int Immunopharmacol; 2002 Dec; 2(13-14):1919-29. PubMed ID: 12489805
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The C-terminal fragment of the Alzheimer's disease amyloid protein precursor is degraded by a proteasome-dependent mechanism distinct from gamma-secretase.
    Nunan J; Shearman MS; Checler F; Cappai R; Evin G; Beyreuther K; Masters CL; Small DH
    Eur J Biochem; 2001 Oct; 268(20):5329-36. PubMed ID: 11606195
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of gamma-secretase as a therapeutic intervention for Alzheimer's disease: prospects, limitations and strategies.
    Evin G; Sernee MF; Masters CL
    CNS Drugs; 2006; 20(5):351-72. PubMed ID: 16696577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. beta-Secretase, APP and Abeta in Alzheimer's disease.
    Vassar R
    Subcell Biochem; 2005; 38():79-103. PubMed ID: 15709474
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The beta-secretase, BACE: a prime drug target for Alzheimer's disease.
    Vassar R
    J Mol Neurosci; 2001 Oct; 17(2):157-70. PubMed ID: 11816789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic options in Alzheimer's disease.
    Moreira PI; Zhu X; Nunomura A; Smith MA; Perry G
    Expert Rev Neurother; 2006 Jun; 6(6):897-910. PubMed ID: 16784412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protease inhibitors as potential disease-modifying therapeutics for Alzheimer's disease.
    Beher D; Graham SL
    Expert Opin Investig Drugs; 2005 Nov; 14(11):1385-409. PubMed ID: 16255678
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beta-secretase (BACE) as a drug target for Alzheimer's disease.
    Vassar R
    Adv Drug Deliv Rev; 2002 Dec; 54(12):1589-602. PubMed ID: 12453676
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE.
    Vassar R; Bennett BD; Babu-Khan S; Kahn S; Mendiaz EA; Denis P; Teplow DB; Ross S; Amarante P; Loeloff R; Luo Y; Fisher S; Fuller J; Edenson S; Lile J; Jarosinski MA; Biere AL; Curran E; Burgess T; Louis JC; Collins F; Treanor J; Rogers G; Citron M
    Science; 1999 Oct; 286(5440):735-41. PubMed ID: 10531052
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alzheimer's disease.
    De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
    Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Processing of amyloid precursor protein as a biochemical link between atherosclerosis and Alzheimer's disease.
    Jans DM; Martinet W; Van De Parre TJ; Herman AG; Bult H; Kockx MM; De Meyer GR
    Cardiovasc Hematol Disord Drug Targets; 2006 Mar; 6(1):21-34. PubMed ID: 16724933
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amyloid-β protein (Aβ) Glu11 is the major β-secretase site of β-site amyloid-β precursor protein-cleaving enzyme 1(BACE1), and shifting the cleavage site to Aβ Asp1 contributes to Alzheimer pathogenesis.
    Deng Y; Wang Z; Wang R; Zhang X; Zhang S; Wu Y; Staufenbiel M; Cai F; Song W
    Eur J Neurosci; 2013 Jun; 37(12):1962-9. PubMed ID: 23773065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Therapy of Alzheimer disease].
    Kovács T
    Neuropsychopharmacol Hung; 2009 Mar; 11(1):27-33. PubMed ID: 19731816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The search for gamma-secretase and development of inhibitors.
    Tsai JY; Wolfe MS; Xia W
    Curr Med Chem; 2002 Jun; 9(11):1087-106. PubMed ID: 12052174
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Secretase as a target for Alzheimer's disease.
    Wolfe MS
    Curr Top Med Chem; 2002 Apr; 2(4):371-83. PubMed ID: 11966461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.